Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

被引：0
|
作者：
Claus-Henning Köhne
Meinolf Karthaus
Laurent Mineur
Josef Thaler
Marc Van den Eynde
Javier Gallego
Reija Koukakis
Marloes Berkhout
Ralf-Dieter Hofheinz
机构：
[1] Klinikum Oldenburg,Department of Oncology and Haematology
[2] Städtisches Klinikum München,Department of Hematology and Oncology
[3] Institut Sainte Catherine,Département de Cancérologie Digestive
[4] Klinikum Wels-Grieskirchen,Internal Medicine IV (Hematology and Medical Oncology)
[5] Cliniques Universitaires Saint-Luc UCL,Department of Gastroenterology and Medical Oncology, Institut Roi Albert II
[6] Hospital General Universitario de Elche,Servicio de Oncología Médica
[7] Amgen Ltd,Department of Biostatistics
[8] Amgen B.V.,Medical Development
[9] Tagestherapiezentrum,undefined
[10] Interdisziplinäres Tumorzentrum,undefined
[11] Universitätsmedizin Mannheim,undefined
来源：
Drugs in R&D | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [21] Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
    Julien Taieb
    Fernando Rivera
    Salvatore Siena
    Meinolf Karthaus
    Manuel Valladares-Ayerbes
    Javier Gallego
    Michael Geissler
    Reija Koukakis
    Gaston Demonty
    Marc Peeters
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 321 - 335
  • [22] Genomic alterations on first-line panitumumab plus FOLFIRI in metastatic colorectal cancer
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    Malapelle, Umberto
    Rosati, Gerardo
    Lotesoriere, Claudio
    Tamburini, Emiliano
    Colombo, Alfredo
    Pepe, Francesco
    Cardone, Claudia
    Leone, Alessandra
    Vitagliano, Carlo
    Russo, Gianluca
    Troncone, Giancarlo
    Giannarelli, Diana
    De Stefano, Alfonso
    Budillon, Alfredo
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
    Manca, Paolo
    Corallo, Salvatore
    Randon, Giovanni
    Lonardi, Sara
    Cremolini, Chiara
    Rimassa, Lorenza
    Bergamo, Francesca
    Antoniotti, Carlotta
    Smiroldo, Valeria
    Zaniboni, Alberto
    Murialdo, Roberto
    Tampellini, Marco
    Tomasello, Gianluca
    Clavarezza, Matteo
    Racca, Patrizia
    Antista, Maria
    Raimondi, Alessandra
    Prisciandaro, Michele
    Pagani, Filippo
    Palermo, Federica
    Greco, Francesca Gabriella
    Vaiani, Marta
    Di Bartolomeo, Maria
    de Braud, Filippo
    Calareso, Giuseppina
    Morano, Federica
    Pietrantonio, Filippo
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 31 - 40
  • [24] Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
    Peeters, Marc
    Price, Timothy
    Taieb, Julien
    Geissler, Michael
    Rivera, Fernando
    Canon, Jean-Luc
    Pentheroudakis, George
    Koukakis, Reija
    Burdon, Peter
    Siena, Salvatore
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 303 - 312
  • [25] Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
    Marc Peeters
    Timothy Price
    Julien Taieb
    Michael Geissler
    Fernando Rivera
    Jean-Luc Canon
    George Pentheroudakis
    Reija Koukakis
    Peter Burdon
    Salvatore Siena
    British Journal of Cancer, 2018, 119 : 303 - 312
  • [26] An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials
    Rivera, F.
    Karthaus, M.
    Valladares-Ayerbes, M.
    Gallego, J.
    Koukakis, R.
    Demonty, G.
    Douillard, J. -Y.
    ANNALS OF ONCOLOGY, 2016, 27 : 114 - 114
  • [27] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [28] Impact of primary tumour location (PTL) on response and resection outcomes in metastatic colorectal cancer (mCRC) patients (pts) receiving first-line panitumumab (Pmab) treatment
    Geissler, M.
    Peeters, M.
    Price, T.
    Taieb, J.
    Rivera, F.
    Canon, J. -L.
    Koukakis, R.
    Burdon, P.
    Siena, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 164 - 164
  • [29] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [30] Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    De Stefano, Alfonso
    Rosati, Gerardo
    Lolli, Ivan
    Tamburini, Emiliano
    Colombo, Alfredo
    Santini, Daniele
    Silvestro, Lucrezia
    Facchini, Gaetano
    Mannavola, Francesco
    Febbraro, Antonio
    Troncone, Giancarlo
    Sobrero, Alberto F.
    Giannarelli, Diana
    Budillon, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345